Compass Therapeutics, Inc.
CMPX
$1.75
$0.052.94%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 850.00K | 850.00K | 850.00K | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 850.00K | 850.00K | 850.00K | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 850.00K | 850.00K | 850.00K | -- | -- |
| SG&A Expenses | 15.13M | 14.56M | 14.03M | 12.42M | 12.25M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 57.48M | 56.30M | 55.98M | 53.43M | 50.37M |
| Operating Income | -56.63M | -55.45M | -55.13M | -53.43M | -50.37M |
| Income Before Tax | -49.38M | -47.76M | -47.24M | -45.44M | -42.49M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -49.38 | -47.76 | -47.24 | -45.44 | -42.49 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -49.38M | -47.76M | -47.24M | -45.44M | -42.49M |
| EBIT | -56.63M | -55.45M | -55.13M | -53.43M | -50.37M |
| EBITDA | -56.04M | -54.84M | -54.50M | -52.77M | -49.67M |
| EPS Basic | -0.36 | -0.36 | -0.36 | -0.36 | -0.34 |
| Normalized Basic EPS | -0.23 | -0.23 | -0.23 | -0.22 | -0.21 |
| EPS Diluted | -0.36 | -0.36 | -0.36 | -0.36 | -0.34 |
| Normalized Diluted EPS | -0.23 | -0.23 | -0.23 | -0.22 | -0.21 |
| Average Basic Shares Outstanding | 548.41M | 533.74M | 523.58M | 512.72M | 502.48M |
| Average Diluted Shares Outstanding | 548.41M | 533.74M | 523.58M | 512.72M | 502.48M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |